Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world

Anselm K. Gitt, Dominik Lautsch, Jean Ferrières, Gaetano M. De Ferrari, Ami Vyas, Carl A. Baxter, Lori D. Bash, Veronica Ashton, Martin Horack, Wael Almahmeed, Fu Tien Chiang, Kian Keong Poh, Philippe Brudi, Baishali Ambegaonkar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

DYSIS II ACS was a longitudinal, observational study in 3867 patients from 18 countries. They were being hospitalized after suffering an acute coronary syndrome. Evaluations were performed at the time of admission and again 120±15 days following the date of admission (the follow-up time point). 2521 patients were on active lipid lowering treatment (LLT) at admission. Mean atorvastatin dose was 22 mg per day and 2.7% received ezetimibe in combination with a statin. At discharge from hospital, 3767 patients received LLT expressed as a mean atorvastatin dose of 36 mg per day with 4.8% receiving ezetimibe on top of a statin. After 120 days, intensity in lipid lowering treatment was reduced to 32 mg per day with 4.9% of the patients receiving ezetimibe and a statin. Of note, during this 4-month follow up period, only 32% of all patients received laboratory lipid testing. 37% attained the low density lipoprotein cholesterol (LDL-C) target value of <70 mg/dl after 120 days. There are differences in the therapy administered as well as in the switch strategies when comparing the data from the respective countries studied. Conclusions Only one in three patients achieved the LDL-C target value following only marginal improvements in atorvastatin dose or combination therapy after an ACS event.

Original languageEnglish
Pages (from-to)369-375
Number of pages7
JournalData in Brief
Volume16
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Acute Coronary Syndrome
LDL Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Therapeutics
Observational Studies
Longitudinal Studies
Ezetimibe
Atorvastatin Calcium

Keywords

  • Global
  • Low-density lipoprotein cholesterol
  • Region
  • Statins
  • Treatment target

ASJC Scopus subject areas

  • General

Cite this

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world. / Gitt, Anselm K.; Lautsch, Dominik; Ferrières, Jean; De Ferrari, Gaetano M.; Vyas, Ami; Baxter, Carl A.; Bash, Lori D.; Ashton, Veronica; Horack, Martin; Almahmeed, Wael; Chiang, Fu Tien; Poh, Kian Keong; Brudi, Philippe; Ambegaonkar, Baishali.

In: Data in Brief, Vol. 16, 01.02.2018, p. 369-375.

Research output: Contribution to journalArticle

Gitt, AK, Lautsch, D, Ferrières, J, De Ferrari, GM, Vyas, A, Baxter, CA, Bash, LD, Ashton, V, Horack, M, Almahmeed, W, Chiang, FT, Poh, KK, Brudi, P & Ambegaonkar, B 2018, 'Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world', Data in Brief, vol. 16, pp. 369-375. https://doi.org/10.1016/j.dib.2017.11.034
Gitt, Anselm K. ; Lautsch, Dominik ; Ferrières, Jean ; De Ferrari, Gaetano M. ; Vyas, Ami ; Baxter, Carl A. ; Bash, Lori D. ; Ashton, Veronica ; Horack, Martin ; Almahmeed, Wael ; Chiang, Fu Tien ; Poh, Kian Keong ; Brudi, Philippe ; Ambegaonkar, Baishali. / Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world. In: Data in Brief. 2018 ; Vol. 16. pp. 369-375.
@article{462af5edf5f44991bc33925465ff9fe3,
title = "Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world",
abstract = "DYSIS II ACS was a longitudinal, observational study in 3867 patients from 18 countries. They were being hospitalized after suffering an acute coronary syndrome. Evaluations were performed at the time of admission and again 120±15 days following the date of admission (the follow-up time point). 2521 patients were on active lipid lowering treatment (LLT) at admission. Mean atorvastatin dose was 22 mg per day and 2.7{\%} received ezetimibe in combination with a statin. At discharge from hospital, 3767 patients received LLT expressed as a mean atorvastatin dose of 36 mg per day with 4.8{\%} receiving ezetimibe on top of a statin. After 120 days, intensity in lipid lowering treatment was reduced to 32 mg per day with 4.9{\%} of the patients receiving ezetimibe and a statin. Of note, during this 4-month follow up period, only 32{\%} of all patients received laboratory lipid testing. 37{\%} attained the low density lipoprotein cholesterol (LDL-C) target value of <70 mg/dl after 120 days. There are differences in the therapy administered as well as in the switch strategies when comparing the data from the respective countries studied. Conclusions Only one in three patients achieved the LDL-C target value following only marginal improvements in atorvastatin dose or combination therapy after an ACS event.",
keywords = "Global, Low-density lipoprotein cholesterol, Region, Statins, Treatment target",
author = "Gitt, {Anselm K.} and Dominik Lautsch and Jean Ferri{\`e}res and {De Ferrari}, {Gaetano M.} and Ami Vyas and Baxter, {Carl A.} and Bash, {Lori D.} and Veronica Ashton and Martin Horack and Wael Almahmeed and Chiang, {Fu Tien} and Poh, {Kian Keong} and Philippe Brudi and Baishali Ambegaonkar",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.dib.2017.11.034",
language = "English",
volume = "16",
pages = "369--375",
journal = "Data in Brief",
issn = "2352-3409",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world

AU - Gitt, Anselm K.

AU - Lautsch, Dominik

AU - Ferrières, Jean

AU - De Ferrari, Gaetano M.

AU - Vyas, Ami

AU - Baxter, Carl A.

AU - Bash, Lori D.

AU - Ashton, Veronica

AU - Horack, Martin

AU - Almahmeed, Wael

AU - Chiang, Fu Tien

AU - Poh, Kian Keong

AU - Brudi, Philippe

AU - Ambegaonkar, Baishali

PY - 2018/2/1

Y1 - 2018/2/1

N2 - DYSIS II ACS was a longitudinal, observational study in 3867 patients from 18 countries. They were being hospitalized after suffering an acute coronary syndrome. Evaluations were performed at the time of admission and again 120±15 days following the date of admission (the follow-up time point). 2521 patients were on active lipid lowering treatment (LLT) at admission. Mean atorvastatin dose was 22 mg per day and 2.7% received ezetimibe in combination with a statin. At discharge from hospital, 3767 patients received LLT expressed as a mean atorvastatin dose of 36 mg per day with 4.8% receiving ezetimibe on top of a statin. After 120 days, intensity in lipid lowering treatment was reduced to 32 mg per day with 4.9% of the patients receiving ezetimibe and a statin. Of note, during this 4-month follow up period, only 32% of all patients received laboratory lipid testing. 37% attained the low density lipoprotein cholesterol (LDL-C) target value of <70 mg/dl after 120 days. There are differences in the therapy administered as well as in the switch strategies when comparing the data from the respective countries studied. Conclusions Only one in three patients achieved the LDL-C target value following only marginal improvements in atorvastatin dose or combination therapy after an ACS event.

AB - DYSIS II ACS was a longitudinal, observational study in 3867 patients from 18 countries. They were being hospitalized after suffering an acute coronary syndrome. Evaluations were performed at the time of admission and again 120±15 days following the date of admission (the follow-up time point). 2521 patients were on active lipid lowering treatment (LLT) at admission. Mean atorvastatin dose was 22 mg per day and 2.7% received ezetimibe in combination with a statin. At discharge from hospital, 3767 patients received LLT expressed as a mean atorvastatin dose of 36 mg per day with 4.8% receiving ezetimibe on top of a statin. After 120 days, intensity in lipid lowering treatment was reduced to 32 mg per day with 4.9% of the patients receiving ezetimibe and a statin. Of note, during this 4-month follow up period, only 32% of all patients received laboratory lipid testing. 37% attained the low density lipoprotein cholesterol (LDL-C) target value of <70 mg/dl after 120 days. There are differences in the therapy administered as well as in the switch strategies when comparing the data from the respective countries studied. Conclusions Only one in three patients achieved the LDL-C target value following only marginal improvements in atorvastatin dose or combination therapy after an ACS event.

KW - Global

KW - Low-density lipoprotein cholesterol

KW - Region

KW - Statins

KW - Treatment target

UR - http://www.scopus.com/inward/record.url?scp=85035803596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035803596&partnerID=8YFLogxK

U2 - 10.1016/j.dib.2017.11.034

DO - 10.1016/j.dib.2017.11.034

M3 - Article

AN - SCOPUS:85035803596

VL - 16

SP - 369

EP - 375

JO - Data in Brief

JF - Data in Brief

SN - 2352-3409

ER -